Analysis reveals significant safety signals in multiple myeloma therapies using teclistamab, talquetamab, and elranatamab, indicating important considerations for patient care.
Key Points
Safety signals varied among bispecific antibodies, with distinct adverse events associated with each treatment.
In total, 2,789,182 adverse event reports were retrieved, revealing significant associations in various disorder categories.
Analysis employed proportional reporting and reporting odds ratios to identify safety signals in the FAERS database.
Findings suggest novel safety signals that may inform clinical practice and treatment decisions for multiple myeloma.